Agios Publishes 2023 Environmental, Social and Governance (ESG) Report
– Report Highlights Continued Progress on Patient Access, Health Equity, Diversity and Flexibility –
– Aligns with the
“As an early adopter of ESG reporting among small to mid-sized biopharma companies, Agios continues to set the bar high and advance initiatives designed to positively impact the patients we serve, our employees, our communities and our world,” said
Key highlights of the report include:
- Patient Access: Following the approval of PYRUKYND® (mitapivat) in the
U.S. , EU, andGreat Britain – the first disease-modifying treatment for adults with pyruvate kinase deficiency, a rare blood disorder – Agios is dedicated to ensuring patient access for this therapy. The company is providing insurance coverage support and copay assistance for eligibleU.S. patients with commercial insurance, free product for eligible uninsured or underinsured patients in theU.S. , and free product for eligible patients in the EU andGreat Britain via a Global Managed Access Program (GMAP). - Health Equity: Agios is focused on centering diverse patient voices and advancing equitable healthcare for all. The ESG Report highlights how this approach is applied across clinical trials, health economics and outcomes research, and patient advocacy, clinical and community partnerships.
- Diversity & Flexibility: Agios is committed to making the company a great place to work for every team member, regardless of their representative, experiential or cognitive differences. The ESG Report details how the company supports diversity at all stages of the employee journey – from talent acquisition to employee development to promotions – as well as through the company’s industry-leading approach to flexibility.
Agios’ ESG program is overseen by its board of directors. The board receives updates on ESG and sustainability from the executive leadership team, including Agios’ chief executive officer, chief financial officer and chief people officer, as well as the leader of the cross-functional ESG working group made up of individuals representing the entire organization, including clinical development, market access, human resources, legal, information technology, facilities, technical operations and external communications.
To learn more about ESG at Agios, read the full report here.
About Agios
Agios is a biopharmaceutical company that is fueled by connections. The Agios team cultivates strong bonds with patient communities, healthcare professionals, partners and colleagues to discover, develop and deliver therapies for rare diseases. In the
Investor & Media Contact
Senior Director, Corporate Communications
Jessica.Rennekamp@agios.com

Source: Agios Pharmaceuticals, Inc.